These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19153917

  • 1. Dopamine vs noradrenaline: inverted-U effects and ADHD theories.
    Levy F.
    Aust N Z J Psychiatry; 2009 Feb; 43(2):101-8. PubMed ID: 19153917
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychiatry; 2006 Feb; 67 Suppl 8():32-8. PubMed ID: 16961428
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM.
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract] [Full Text] [Related]

  • 4. Catecholamine influences on dorsolateral prefrontal cortical networks.
    Arnsten AF.
    Biol Psychiatry; 2011 Jun 15; 69(12):e89-99. PubMed ID: 21489408
    [Abstract] [Full Text] [Related]

  • 5. What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications.
    Levy F.
    Aust N Z J Psychiatry; 2007 Jan 15; 41(1):10-6. PubMed ID: 17464676
    [Abstract] [Full Text] [Related]

  • 6. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychopharmacol; 2008 Jun 15; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [Abstract] [Full Text] [Related]

  • 7. Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.
    Gamo NJ, Wang M, Arnsten AF.
    J Am Acad Child Adolesc Psychiatry; 2010 Oct 15; 49(10):1011-23. PubMed ID: 20855046
    [Abstract] [Full Text] [Related]

  • 8. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
    Ruocco LA, Carnevale UA, Treno C, Sadile AG, Melisi D, Arra C, Ibba M, Schirru C, Carboni E.
    Behav Brain Res; 2010 Jun 26; 210(1):99-106. PubMed ID: 20156489
    [Abstract] [Full Text] [Related]

  • 9. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
    Castellanos FX, Acosta MT.
    Rev Neurol; 2011 Mar 01; 52 Suppl 1():S155-60. PubMed ID: 21365598
    [Abstract] [Full Text] [Related]

  • 10. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
    Arnsten AF.
    J Clin Psychiatry; 2006 Mar 01; 67 Suppl 8():7-12. PubMed ID: 16961424
    [Abstract] [Full Text] [Related]

  • 11. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.
    Liu LL, Yang J, Lei GF, Wang GJ, Wang YW, Sun RP.
    Basic Clin Pharmacol Toxicol; 2008 Jun 01; 102(6):527-32. PubMed ID: 18346050
    [Abstract] [Full Text] [Related]

  • 12. COMT x DRD4 epistasis impacts prefrontal cortex function underlying response control.
    Heinzel S, Dresler T, Baehne CG, Heine M, Boreatti-Hümmer A, Jacob CP, Renner TJ, Reif A, Lesch KP, Fallgatter AJ, Ehlis AC.
    Cereb Cortex; 2013 Jun 01; 23(6):1453-62. PubMed ID: 22617852
    [Abstract] [Full Text] [Related]

  • 13. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
    Arnsten AF, Scahill L, Findling RL.
    J Child Adolesc Psychopharmacol; 2007 Aug 01; 17(4):393-406. PubMed ID: 17822336
    [Abstract] [Full Text] [Related]

  • 14. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex.
    Devoto P, Flore G, Pira L, Longu G, Gessa GL.
    Eur J Pharmacol; 2004 Mar 08; 487(1-3):105-11. PubMed ID: 15033381
    [Abstract] [Full Text] [Related]

  • 15. Stimulant side effects and inverted-U: implications for ADHD guidelines.
    Levy F.
    Aust N Z J Psychiatry; 2013 Mar 08; 47(3):217-21. PubMed ID: 22689336
    [Abstract] [Full Text] [Related]

  • 16. A current update on ADHD pharmacogenomics.
    Kieling C, Genro JP, Hutz MH, Rohde LA.
    Pharmacogenomics; 2010 Mar 08; 11(3):407-19. PubMed ID: 20235795
    [Abstract] [Full Text] [Related]

  • 17. Schizotypy, attention deficit hyperactivity disorder, and dopamine genes.
    Ettinger U, Joober R, DE Guzman R, O'driscoll GA.
    Psychiatry Clin Neurosci; 2006 Dec 08; 60(6):764-7. PubMed ID: 17109713
    [Abstract] [Full Text] [Related]

  • 18. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.
    Arnsten AF, Li BM.
    Biol Psychiatry; 2005 Jun 01; 57(11):1377-84. PubMed ID: 15950011
    [Abstract] [Full Text] [Related]

  • 19. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J.
    J Clin Psychopharmacol; 2008 Jun 01; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [Abstract] [Full Text] [Related]

  • 20. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
    Arnsten AF, Pliszka SR.
    Pharmacol Biochem Behav; 2011 Aug 01; 99(2):211-6. PubMed ID: 21295057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.